{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:08:27Z","timestamp":1793394507368,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32070818"],"award-info":[{"award-number":["32070818"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82460142"],"award-info":[{"award-number":["82460142"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32170662"],"award-info":[{"award-number":["32170662"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.bbadis.2026.168182","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T16:29:44Z","timestamp":1770395384000},"page":"168182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Oncogenic epigenetic factor EP300 is a potential therapeutic target for bladder carcinoma"],"prefix":"10.1016","volume":"1872","author":[{"given":"Qing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingzhou","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongjie","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianbin","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxi","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangsheng","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunming","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bbadis.2026.168182_bb0005","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41585-022-00578-1","article-title":"Recurrence mechanisms of non-muscle-invasive bladder cancer \u2014 a clinical perspective [J]","volume":"19","author":"Teoh","year":"2022","journal-title":"Nat. Rev. Urol."},{"issue":"3","key":"10.1016\/j.bbadis.2026.168182_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bbadis.2026.168182_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217506","article-title":"Integrative analysis of patient-derived tumoroids and ex vivo organoid modelling of ARID1A loss in bladder cancer reveals therapeutic molecular targets","volume":"614","author":"Scholtes","year":"2025","journal-title":"Cancer Lett."},{"issue":"6","key":"10.1016\/j.bbadis.2026.168182_bb0020","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aar5598","article-title":"X chromosome protects against bladder cancer in females via aKDM6A-dependent epigenetic mechanism","volume":"4","author":"Kaneko","year":"2018","journal-title":"Sci. Adv."},{"issue":"2","key":"10.1016\/j.bbadis.2026.168182_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2018.12.009","article-title":"Targeting the vulnerability of glutathione metabolism in ARID1A-deficient cancers","volume":"35","author":"Ogiwara","year":"2019","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bbadis.2026.168182_bb0030","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41588-024-02015-y","article-title":"Loss of Kmt2c or Kmt2d primes urothelium for tumorigenesis and redistributes KMT2A\u2013menin to bivalent promoters","volume":"57","author":"Wang","year":"2025","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.bbadis.2026.168182_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.04.033","article-title":"Time-resolved analysis reveals rapid dynamics and broad scope of the CBP\/p300 acetylome","volume":"174","author":"Weinert","year":"2018","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.bbadis.2026.168182_bb0040","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1158\/2159-8290.CD-21-0385","article-title":"EP300 selectively controls the enhancer landscape of MYCN-amplified neuroblastoma","volume":"12","author":"Durbin","year":"2022","journal-title":"Cancer Discov."},{"issue":"17","key":"10.1016\/j.bbadis.2026.168182_bb0045","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1182\/blood-2012-02-413187","article-title":"Interaction of c-Myb with p300 is required for the induction of acute myeloid leukemia (AML) by human AML oncogenes","volume":"123","author":"Pattabiraman","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bbadis.2026.168182_bb0050","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abl4618","article-title":"KIX domain determines a selective tumor-promoting role for EP300 and its vulnerability in small cell lung cancer","volume":"8","author":"Kim","year":"2022","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.bbadis.2026.168182_bb0055","doi-asserted-by":"crossref","DOI":"10.1038\/s41420-024-01940-5","article-title":"The epigenetic regulators EP300\/CREBBP represent promising therapeutic targets in MLL-rearranged acute myeloid leukemia","volume":"10","author":"Wu","year":"2024","journal-title":"Cell Death Discov."},{"issue":"4","key":"10.1016\/j.bbadis.2026.168182_bb0060","article-title":"Genetic dysregulation of EP300 in cancers in light of cancer epigenome control \u2013 targeting of p300-proficient and -deficient cancers","volume":"32","author":"Gronkowska","year":"2024","journal-title":"Mol. Ther. Oncolytics"},{"issue":"8","key":"10.1016\/j.bbadis.2026.168182_bb0065","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s00018-017-2717-4","article-title":"CREBBP and p300 lysine acetyl transferases in the DNA damage response","volume":"75","author":"Dutto","year":"2017","journal-title":"Cell. Mol. Life Sci."},{"issue":"10","key":"10.1016\/j.bbadis.2026.168182_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11101539","article-title":"PARP1 co-regulates EP300\u2013BRG1-dependent transcription of genes involved in breast cancer cell proliferation and DNA repair","volume":"11","author":"Sobczak","year":"2019","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.bbadis.2026.168182_bb0075","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1158\/1078-0432.CCR-22-3836","article-title":"A tumor-suppressive molecular axis EP300\/circRERE\/miR-6837-3p\/MAVS activates type I IFN pathway and antitumor immunity to suppress colorectal cancer","volume":"29","author":"Ding","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbadis.2026.168182_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113914","article-title":"A novel histone acetyltransferase inhibitor A485 improves sensitivity of non-small-cell lung carcinoma cells to TRAIL","volume":"175","author":"Zhang","year":"2020","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.bbadis.2026.168182_bb0085","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11523-023-00949-7","article-title":"FT-6876, a potent and selective inhibitor of CBP\/p300, is active in preclinical models of androgen receptor-positive breast cancer","volume":"18","author":"Caligiuri","year":"2023","journal-title":"Target. Oncol."},{"issue":"3","key":"10.1016\/j.bbadis.2026.168182_bb0090","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1158\/1541-7786.MCR-18-0719","article-title":"CREBBP\/EP300 bromodomain inhibition affects the proliferation of AR-positive breast cancer cell lines","volume":"17","author":"Garcia-Carpizo","year":"2019","journal-title":"Mol. Cancer Res."},{"issue":"3","key":"10.1016\/j.bbadis.2026.168182_bb0095","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.18632\/aging.102728","article-title":"EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients","volume":"12","author":"Zhu","year":"2020","journal-title":"Aging (Albany NY)"},{"issue":"3","key":"10.1016\/j.bbadis.2026.168182_bb0100","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.gendis.2018.10.002","article-title":"Acetylation of H3K4, H3K9, and H3K27 mediated by p300 regulates the expression of GATA4 in cardiocytes","volume":"6","author":"Zhou","year":"2019","journal-title":"Genes Dis."},{"issue":"4","key":"10.1016\/j.bbadis.2026.168182_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041219","article-title":"The role of CREBBP\/EP300 and its therapeutic implications in hematological malignancies","volume":"15","author":"Zhu","year":"2023","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.bbadis.2026.168182_bb0110","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/j.celrep.2018.10.003","article-title":"Brd4\u2019s bromodomains mediate histone H3 acetylation and chromatin remodeling in pluripotent cells through P300 and Brg1","volume":"25","author":"Wu","year":"2018","journal-title":"Cell Rep."},{"issue":"41","key":"10.1016\/j.bbadis.2026.168182_bb0115","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202507549","article-title":"H3K27ac is essential for human naive pluripotency modulated by m6A-driven EP300 expression","volume":"12","author":"An","year":"2025","journal-title":"Adv. Sci."},{"issue":"1","key":"10.1016\/j.bbadis.2026.168182_bb0120","article-title":"MYC reshapes CTCF-mediated chromatin architecture in prostate cancer","volume":"14","author":"Wei","year":"2023","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.bbadis.2026.168182_bb0125","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1093\/nar\/gkw1247","article-title":"H3K27 acetylation activated-long non-coding RNA CCAT1 affects cell proliferation and migration by regulating SPRY4 and HOXB13 expression in esophageal squamous cell carcinoma","volume":"45","author":"Zhang","year":"2017","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.bbadis.2026.168182_bb0130","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-50910-z","article-title":"Super enhancer acquisition drives expression of oncogenic PPP1R15B that regulates protein homeostasis in multiple myeloma","volume":"15","author":"Xiong","year":"2024","journal-title":"Nat. Commun."},{"issue":"7674","key":"10.1016\/j.bbadis.2026.168182_bb0135","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nature24028","article-title":"Discovery of a selective catalytic p300\/CBP inhibitor that targets lineage-specific tumours","volume":"550","author":"Lasko","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bbadis.2026.168182_bb0140","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-89530-8","article-title":"C646 inhibits G2\/M cell cycle-related proteins and potentiates anti-tumor effects in pancreatic cancer","volume":"11","author":"Ono","year":"2021","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.bbadis.2026.168182_bb0145","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.chembiol.2010.03.006","article-title":"Virtual ligand screening of the p300\/CBP histone acetyltransferase: identification of a selective small molecule inhibitor","volume":"17","author":"Bowers","year":"2010","journal-title":"Chem. Biol."},{"issue":"34","key":"10.1016\/j.bbadis.2026.168182_bb0150","doi-asserted-by":"crossref","first-page":"10768","DOI":"10.1073\/pnas.1501956112","article-title":"CBP30, a selective CBP\/p300 bromodomain inhibitor, suppresses human Th17 responses","volume":"112","author":"Hammitzsch","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"11","key":"10.1016\/j.bbadis.2026.168182_bb0155","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.7150\/thno.73223","article-title":"Histone acetyltransferases CBP\/p300 in tumorigenesis and CBP\/p300 inhibitors as promising novel anticancer agents","volume":"12","author":"Chen","year":"2022","journal-title":"Theranostics"},{"issue":"11","key":"10.1016\/j.bbadis.2026.168182_bb0160","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1038\/s41401-019-0237-5","article-title":"Y08197 is a novel and selective CBP\/EP300 bromodomain inhibitor for the treatment of prostate cancer","volume":"40","author":"Zou","year":"2019","journal-title":"Acta Pharmacol. Sin."},{"issue":"5","key":"10.1016\/j.bbadis.2026.168182_bb0165","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-20-0751","article-title":"Targeting the p300\/CBP axis in lethal prostate cancer","volume":"11","author":"Welti","year":"2021","journal-title":"Cancer Discov."},{"issue":"12","key":"10.1016\/j.bbadis.2026.168182_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2023.11.001","article-title":"Therapeutic targeting of EP300\/CBP by bromodomain inhibition in hematologic malignancies","volume":"41","author":"Nicosia","year":"2023","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.bbadis.2026.168182_bb0175","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1158\/2159-8290.CD-15-0754","article-title":"Targeting p300 addiction in CBP-deficient cancers causes synthetic lethality by apoptotic cell death due to abrogation of MYC expression","volume":"6","author":"Ogiwara","year":"2016","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.bbadis.2026.168182_bb0180","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-020-07573-y","article-title":"EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer","volume":"20","author":"Ring","year":"2020","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.bbadis.2026.168182_bb0185","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1530\/ERC-19-0488","article-title":"P300 is upregulated by docetaxel and is a target in chemoresistant prostate cancer","volume":"27","author":"Gruber","year":"2020","journal-title":"Endocr. Relat. Cancer"},{"issue":"1","key":"10.1016\/j.bbadis.2026.168182_bb0190","doi-asserted-by":"crossref","DOI":"10.1186\/s10020-023-00608-7","article-title":"Experimental analysis of bladder cancer-associated mutations in EP300 identifies EP300-R1627W as a driver mutation","volume":"29","author":"Luo","year":"2023","journal-title":"Mol. Med."},{"issue":"2","key":"10.1016\/j.bbadis.2026.168182_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2024.01.005","article-title":"Small-molecule CBP\/p300 histone acetyltransferase inhibition mobilizes leukocytes from the bone marrow via the endocrine stress response","volume":"57","author":"Jaschke","year":"2024","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.bbadis.2026.168182_bb0200","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"issue":"10","key":"10.1016\/j.bbadis.2026.168182_bb0205","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1093\/bioinformatics\/btac166","article-title":"Analysing high-throughput sequencing data in Python with HTSeq 2.0","volume":"38","author":"Putri","year":"2022","journal-title":"Bioinformatics"},{"issue":"2","key":"10.1016\/j.bbadis.2026.168182_bb0210","first-page":"1","article-title":"edgeR 4.0: powerful differential analysis of sequencing data with expanded functionality and improved support for small counts and larger datasets","volume":"53","author":"Chen","year":"2025","journal-title":"Neuclic Acids Res."},{"issue":"7","key":"10.1016\/j.bbadis.2026.168182_bb0215","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkv007","article-title":"Limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"10.1016\/j.bbadis.2026.168182_bb0220","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41596-024-01020-z","article-title":"Using clusterProfiler to characterize multiomics data","volume":"19","author":"Xu","year":"2024","journal-title":"Nat. Protoc."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092544392600030X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092544392600030X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:24:14Z","timestamp":1791059054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092544392600030X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S092544392600030X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2026.168182","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncogenic epigenetic factor EP300 is a potential therapeutic target for bladder carcinoma","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbadis.2026.168182","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"168182"}}